End of Induction (EOI) Curie Scores
For patients undergoing tandem AHCT, the median Curie score at EOI was 0 (range 0 to 23) and the median change in Curie score was -11.5 (range -27 to 0) from diagnosis to EOI (FIGURE 1B) . The optimal CS cut point at EOI was 0 for recipients of tandem AHCT. Three-year EFS was significantly greater in patients with a CS=0 (n=48) vs >0 (n=32) at EOI, 72.9±6.4% vs 46.5±9.1%, p=0.002. Similarly, 3-year OS was superior in patients with a CS=0 vs >0 at EOI, 83.1±5.5% vs 55.9±9.0%, p=0.015 (TABLE 2) (FIGURE 3A) . When restricting the analysis to the 56 patients who received tandem transplant and immunotherapy, EOI CS remained significant, with 3-year EFS 81.1±6.4% vs 57.9±11.3% for those with a CS=0 (n=37) vs CS>0 (n=19) respectively; p=0.016. No statistical difference was noted in OS for this same population, p=0.06.
Outcomes based upon CS at EOI are shown by MYCN status(TABLE 3) (FIGURE 3B-C) . In this small cohort of patients with either MYCN- amplified or MYCN- NA disease, 3-year EFS was superior in patients with a CS=0 (vs >0) at EOI.
Relative Curie scores, including either a 50% or 75% reduction in CS from diagnosis to EOI, were not associated with a statistically significant difference in EFS or OS in recipients of tandem AHCT(TABLE 2) .